NeuroSense Therapeutics (NRSN) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's.

• Lead candidate PrimeC is a novel oral fixed-dose combination of ciprofloxacin and celecoxib, targeting ALS through multiple disease pathways.

• PrimeC has orphan drug designation from both FDA and EMA, and SME status from EMA.

• Pipeline includes additional candidates for Alzheimer's and Parkinson's, following a similar combined product strategy.

Financial performance and metrics

• April 2024: Raised $4.47 million gross in a registered direct offering at $1.50 per share and $1.4999 per pre-funded warrant.

• August 2024: Raised $600,000 net in a private placement at $0.75 per share and warrant.

• As of June 30, 2024, pro forma as adjusted cash was $13.95 million, with total capitalization of $11.08 million after the offering.

• Recurring losses and expectation of significant additional losses raise substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• May receive up to $30 million in gross proceeds from sales of ordinary shares to YA under the Standby Equity Purchase Agreement.

• Proceeds intended for continued development of pipeline products, advancement of new programs, business development, and general corporate purposes.

• Management has broad discretion in allocation of net proceeds.